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Objective  The Subcommittee on the Survey of Nuclear Medical Practice in Japan has performed 
a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey current nuclear 
medicine practice and its changes over the years. 
Methods  The subcommittee sent questionnaires, including the number and category of 
examinations as well as the kind and dose of the radiopharmaceuticals during the 30 days of June 
2012, to all of the nuclear medicine institutes. The total numbers for the year 2012 were then 
estimated. 
Results   A total of 1,167 facilities responded to the survey, including the 14 in vitro assay 
institutes and 266 PET centers. The recovery rate was 92%. The number of gamma cameras installed 
was 1,425 in total, with 9% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners 
accounted for 84% and 10.5%, respectively. The number of single-photon tracer studies in 2012 was 
1.15 million which means decrease in 19% in 5 years and 29% in 10 years. All but cerebral perfusion 
study and sentinel lymphoscintigraphy have decreased. Bone scintigraphy was a leading examination 
(37%), followed by cardiac studies (28%) and cerebral perfusion study (18%) in order. SPECT 
studies showed an increase from 42% to 47%. PET centers have also increased from 212 to 295, as 
compared to the last survey. The 135 PET centers have installed one or two in-house cyclotrons. PET 
studies showed 26% increase in 5 years, with oncology accounting for 96%. 18F-FDG accounted for 
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98% (505,990 examinations). PET examinations using 11C-methionine have been increasing, with 
3,352 examinations in 2012. The number of new PET studies using 11C-PIB PET was 
695. 131I-radioiodine targeted therapies showed an increase, including 3,644 patients (54%) for 
thyroid cancer and 4,889 patients (18%) for hyperthyroidism. Out-patient thyroid bed ablation 
therapy with 30 mCi of 131I accounted for 21% of cancer patients. The number of isolation rooms 
decreased from 158 to 135 in 5 years. In vitro radioassays have been declining continuously since 
1992, with the number of studies of 9.0 million in 2012. 
Conclusions  Single-photon examinations showed a continuous tendency toward a decline in the 
survey. In contrast, the number of hybrid SPECT/CT scanner examinations has increased. PET/CT 





The Subcommittee on the Survey of Nuclear Medicine Practice in Japan, the Medical Science and 
Pharmaceutical Committee, the Japan Radioisotope Association (JRIA) has performed a nationwide 
survey of in vivo and in vitro nuclear medicine practice every 5 years since 1982 to provide 
beneficial information on the contemporary status of nuclear medicine practice in Japan [1-9]. The 
seventh survey was recently done in June 2012. A detailed comparison was performed between the 
survey and the previous surveys, analyzing the results. 
 
Methods of survey 
A sheet of questionnaire was sent to every institute, of which information JRIA has, to conduct 
clinical nuclear medicine examinations. The sheets included the survey items such as the numbers, 
the kinds, and injected doses of tracers in the nuclear medicine examination practice during the 
month of June in 2012. The categories of in vivo examinations using single-photon tracers were 
classified into brain or cerebrospinal fluid, salivary, thyroid, parathyroid, lung, heart or great vessels, 
liver or biliary tract, spleen or bone marrow, kidney or urinary tract, adrenal gland, bone or joint, 
gastrointestinal tract, tumor or inflammation, sentinel lymphoscintigraphy, other scintigraphy, and 
sample-counting examination.  
To avoid counting twice the study number, the following was regarded as a single study: a 
study combined with another related study such as thyroid scintigraphy combined with thyroid 
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radioiodine uptake measurement; a study taking serial images such as radionuclide cisternography; a 
study in which the same radiopharmaceutical is injected twice within the same day such as stress and 
rest myocardial perfusion study using technetium-99m (99mTc)-labeled agents, and so on. All of the 
radiopharmaceuticals used, even if commercially available or unavailable, were recommended to be 
described in the questionnaire sheets. 
The number and types of gamma cameras installed at each institute were also asked about. 
In addition, positron emission tomography (PET) and in vitro study, and radionuclide targeted 
therapy were included in the survey. The actual examination number and patients' number per year, 
performed or treated in 2012 were required to fill in the sheet with regard to PET study and 
radionuclide targeted therapy. 
Regarding in vitro study, duplicated sample measurement was regarded as a single test, but 
serial sample measurements in a patient, such as overloading tests, were regarded as they were. 
 
Results 
The total number of institutes, of which information JRIA has as a nuclear medicine institute was 
1,274 (Fig. 1). The breakdown is as follows: 1,170 institutes for in vivo single-photon study and/or 
radionuclide targeted therapy, and 295 for PET study. The former has decreased by 4.0% and the 
latter has increased by 39% in 5 years. The 15 institutes for in vitro study has markedly decreased by 
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69% in 5 years with a continuous decline since 1982. Of the1,274 institutes to which the 
Subcommittee sent a sheet of questionnaire, 1,167 (91.6%) answered the sheet. 
Figure 2 shows the number of the installed gamma cameras, which were obtained from the 
results of the respondents. A total of 1,425 gamma cameras were installed in 1,074 institutes (mean: 
1.3 cameras). Dual-head cameras capable of SPECT acquisition accounted for 79% (Fig 3). The 
number of brand-new hybrid SPECT/CT scanners was 149. Of the 266 respondents with PET system, 
108 have installed one or two cyclotrons, with a total number of 113 cyclotrons, meaning the 
increase of 5 centers installed with a cyclotron since 2007. The number of PET and hybrid PET/CT 
scanners was 374 in the 254 PET centers in the survey of the year, 2012, which means an increase in 
PET or PET/CT scanners by 75 for 5 years, as 299 in 192 PET centers in the survey of the year, 2007. 
The increase is ascribable to the development of the 18F-FDG commercial deliver system during 5 
years.  
The estimated total number of single-photon tracer examinations in 2012 was 1.15 million, 
which means the number of administered radiopharmaceuticals. The result was found to be 18.9% 
decrease in single-photon tracer examinations when compared to that of the last survey in 2007 (Fig. 
4). If the business days for nuclear medicine practice are assumed to be 250 days a year, 
approximately 4,600 studies were done nationwide per day. The categories of the single-photon 
studies are shown in Fig. 5. Bone scintigraphy was a leading examination (38.7%), followed by 
cardiovascular scintigraphy (29.4%) and cerebral SPECT study (18.5%) in order. The number of 
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cerebral SPECT study is stable in the past 15 years. Lymphoscintigraphy, of which sentinel 
lymphoscintigraphy accounted for 84.4%, increased, though the number was small yet. Overall, the 
number of single-tracer examinations except cerebral SPECT and lymphoscintigraphy has decreased, 
with more prominent decrease in tumor/inflammation scintigraphy. 
Figure 6 shows chronological changes for each radiopharmaceutical from 1997 to 
2012. 99mTc-HMDP was used most frequently for bone scintigraphy. Thallium-201 (201Tl) chloride 
was mainly used for myocardial perfusion SPECT, of which 50.0% were carried out as 
electrocardiogram (ECG)-gated study. 99mTc-sestamibi and 99mTc-tetrofosmin were used less 
frequently, but 85.6% and 75.2% for ECG-gated study, respectively. Exercise or pharmacological 
stress test was applied to 69.0% of all of myocardial perfusion SPECT studies. The number 
of 123I-MIBG myocardial scintigraphy has steadily increased. 123I-IMP was most frequently used for 
cerebral perfusion SPECT, though 99mTc-ethylcystenate dimer (ECD) was used with the similar 
frequency. Statistical parametric mapping was used in 75.6% of all of the cerebral perfusion SPECT 
with 15.6% increase, as compared to the data in 2007. 99mTc-galactosyl human serum albumin (GSA) 
was frequently used as a hepatobiliary imaging agent. The number of 99mTc-PMT and 99mTc-phytae 
studies has decreased prominently, but 99mTc-GSA studies minimally. 
The total number of SPECT acquisition studies has decreased because the number of 
single-photon tracers has decreased. However, the percentage of SPECT acquisition has increased 
from 42.3% to 47.2% in 5 years. The percentage of each study is as follows: 77.3% for cerebral study, 
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67.4% for myocardial study, and 52.5% for tumor imaging study (Fig. 7). 
PET studies were used mainly in oncology field, which accounted for 97.7% (Fig. 8). A total 
number of 18F-FDG PET studies was 505,990, which accounted for 99.8% of all PET studies in 2012 
and 25.5% increase as compared to the result in 2007. The use of a 13N tracer was stable in these 10 
years. Studies with an 11C-positron emitter kept on increasing in these 15 years, though the total 
number remained small. The number of 15O-PET studies has been apparently 
decreasing. 11C-methionine and 13N-NH3 were major PET tracers other than 18F-FDG. There was a 
striking increase in 11C-methionine in these 10 years (Fig. 9). In addition, 11C-PIB has been used 
frequently for the diagnosis of Alzheimer's disease in 5 years. 
A total of 340 institutes have the facilities for radionuclide targeted therapy, which means 
the increase by 190 institutes as compared to the result in 2007. In contrast, the number of institutes 
running admission rooms for the therapy has decreased from 66 to 63, with the decrease in the 
admission rooms from 188 to 135 in 10 years. The numbers of patients with thyroid cancer or 
hyperthyroidism who underwent 131I-targeted therapy, were 3,644 and 4,889, respectively, in the year 
from June 1st 2011 to June 30th 2012 (Fig. 10). Of all of the patients with hyperthyroidism, 77% 
were outpatients and underwent 131I-radioiodine targeted therapy. Thyroid ablation therapy for 
outpatients using 131I of 1,110 MBq, which was approved by the government in November 2010, was 
carried out in 764 patients (21.0%). Radionuclide targeted therapy for malignant neuroendocrine 
tumors using 131I-metaiodobenzylguanidine (MIBG) was performed in 34 patients with an increase 
8 
 
by 14 patients as compared the results in 2007. The numbers of bone pain palliative therapy with 89Sr 
and radionuclide targeted therapy for B-cell lymphoma with 90Y-ibritumomab tiuxetan, which were 
approved by the government in 2007 and 2008, respectively, are shown in Fig. 10. 
A total of 9.0 million in vitro radioassays were carried out in the year 2012. The number has 
been decreasing continuously since 1992. In this survey, tumor markers' radioassays were a leading 
group (14.9%), followed by the adrenal function tests' group (14.4%), and reno-vascular regulating 
function tests' group (9.2%) in order. By and large, the number of in vitro radioassays decreased, but 
the number of parathyroid function tests, adrenal function tests, ferrokinetics/hematopoietic tests, 
gonadotropic/placental function tests and cytokine measurements were almost stable in 5 years. The 




The nationwide surveys have been repeatedly performed every five years and the current 
survey was the seventh one. It is estimated that marked changes in nuclear medicine practice have 
occurred because new radiopharmaceuticals and nuclear medicine equipment have devised almost 
every year. The current questionnaire survey was carefully prepared for comparing the results of 
previous surveys as accurately as possible before sending the questionnaire sheets to nuclear 
medicine institutes. For example, multiple studies done by a single administration of a 
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radiopharmaceutical were regarded as a single study to avoid counting twice or three times. 
The number of facilities which utilize single-photon tracers and perform targeted 
radionuclide therapy declined for the first time since the surveys stated in 1982.  The number of 
gamma cameras installed nationwide also declined. Consequently, the total number of single-photon 
tracer studies has been decreasing since 1997 when the fourth survey was conducted. The number of 
single-photon tracer examinations in 2012 was 1.5 million, which means a 19% and 29% decrease 
for 5 years and 10 years, respectively. 
 Bone scintigraphy remains a leading examination, accounting for approximately a third of 
all single-photon examinations. However, its application continues to decrease for 10 years. 
Single-photon scintigraphy for tumor detection has markedly decreased for 20 years. One reason for 
the decrease is explained by increase in use of 18F-FDG PET, of which use was officially approved 
by the government, and covered by the national health insurance for ten types of malignancies in 
April 2002, and then an additional three types of malignancies in April 2006. Another reason might 
be explained by the development of other imaging modalities such as magnetic resonance imaging 
(MRI) or multi-detector row CT.  
Cardiac scintigraphy (cardiovascular nuclear medicine) was the second leading examination. 
Contrary to the definite evidence of myocardial scintigraphy for evaluation of various cardiac 
diseases, its application to cardiac diseases has been decreasing for 10 years, suggesting the necessity 
to inform clinicians of the role cardiac scintigraphy plays in the clinical settings. The decrease in 
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ECG-gated blood pool cardiac imaging is clearly due to the increase in quantitative gated SPECT 
studies. 123I-MIBG scintigraphy showed 1.4-fold increase. The main reason of the increase is 
explained by its use for the differential diagnosis among Parkinson disease, dementia of Lewy body 
disease, and parkinsonism, though the increase in patients with chronic heart disease may be 
attributable for the increase. 
Slight increase was found in cerebral perfusion SPECT studies, likely due to clinical 
demand for the statistical image analysis in diagnosis of cerebral disorders, especially dementia. 
Pulmonary, thyroid, renal (including dynamic study), liver, and bone marrow scintigraphy 
showed a decrease in the number of the studies, probably because of the development and 
nationwide spread of anatomical imaging modalities such as MRI, multi-detector row CT, and 
ultrasonography.  The number of renal static scintigraphy did not change in 5 year, suggesting its 
clinical utility in detecting disease entities such as renal scar. 
The number of adrenal studies was constant, probably because it has been established as a 
diagnostic tool for adrenal disorders. In other words, scintigraphy to evaluate specific organ function, 
which cannot be evaluated by other modalities, survives in the clinical practice of nuclear medicine. 
What should be noted in changes of the recent trends for single-photon studies is steady 
increase in SPECT studies in all kinds of examinations, coupled with the increase in hybrid 
SPECT/CT scanners. Fusion images surely enhance reading performance of images and provide 
clinicians with more accurate information of the disease. Nuclear medicine specialists should 
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improve their reading skills by exploiting these state-of-art techniques.  
The number of PET institutes and its studies dramatically increased just after the 
governmental approval of 18F-FDG for the use of the oncologic use. The coverage of 18F-FDG PET 
study by the national health insurance had started in Japan 2 months prior to the survey in 2002. 
Subsequently, the number of 18F-FDG study increased as predicted at that time. In addition, a 
commercially available 18F-FDG delivery system started in 2005, which also accelerated the use 
of 18F-FDG studies. The current survey confirmed this trend for the increase in 18F-FDG PET study. 
The number of 11C-methionine studies has been steadily increasing in research work in oncology. In 
contrast, the number of 15O-gas PET studies has decreased probably because it is laborious and 
wasteful to do the studies, though 15O-gas PET study was approved by the government with a 
relatively low study cost and covered by the national health insurance in 1996. 
Radionuclide targeted therapy for thyroid cancer has been increasing steadily since 1987. 
Radioiodine targeted therapy for hyperthyroidism showed a rapid increase in number after the 
publication of the guideline in 1998. The guideline says that patients are able to be released from an 
outpatient clinic if those receive 500 MBq of 131I or less. In addition to the guideline publication, 
clinicians' preference and patients' demand are attributable to the increase in radioiodine targeted 
therapy for hyperthyroidism.  
Patients with a high risk of recurrence after total thyroidectomy for differentiated thyroid 
cancer receive a benefit from the guideline of out-patient thyroid ablation published in 2010, 
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resulting in the timely application of thyroid ablation. However, the situation of 131I targeted therapy 
has been deteriorating despite the increase in the patients with thyroid cancer, due to the shortage of 
the admission rooms and a long waiting time until admission.  
The number of institutions conducting in vitro studies has been continuously decreasing 
over the past 30 years. The number of in vitro assays has decreased in all kinds of examinations 
except the examinations of samples with unstable substances or of complicated procedures. The 
trend toward the shift from radioassay to non-radioassay will continue even in the future. If most of 
in vitro radioassays will be concentrated to a few private laboratory centers, more careful and strict 
quality control should be required regarding radioassay in the future. 
 
Conclusions 
It was found out that nuclear medicine practice in Japan has kept on changing in the past 5 
years. We are convinced that this survey report is useful in understanding the current status of the 
nuclear medicine practice and its future trend, and in devising the new strategy to strengthen a role 
nuclear medicine plays in the clinical setting and research work. 
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